XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENT OF INCOME - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]        
Sales $ 14,959 $ 13,154 $ 45,453 $ 35,183
Costs, Expenses and Other        
Cost of sales 3,934 3,450 13,530 9,752
Selling, general and administrative 2,520 2,336 7,355 6,804
Research and development 4,399 2,445 9,773 9,177
Restructuring costs 94 107 288 487
Other (income) expense, net 429 (450) 1,576 (1,007)
Total Costs, Expenses and Other 11,376 7,888 32,522 25,213
Income from Continuing Operations Before Taxes 3,583 5,266 12,931 9,970
Taxes on Income from Continuing Operations 330 695 1,423 1,436
Net Income from Continuing Operations 3,253 4,571 11,508 8,534
Less: Net Income Attributable to Noncontrolling Interests 5 4 6 9
Net Income from Continuing Operations Attributable to Merck & Co., Inc. 3,248 4,567 11,502 8,525
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests 0 0 0 766
Net Income Attributable to Merck & Co., Inc. $ 3,248 $ 4,567 $ 11,502 $ 9,291
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders:        
Income from Continuing Operations (in dollars per share) $ 1.28 $ 1.81 $ 4.55 $ 3.37
Income from Discontinued Operations (in dollars per share) 0 0 0 0.30
Net Income (in dollars per share) 1.28 1.81 4.55 3.67
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders:        
Income from Continuing Operations (in dollars per share) 1.28 1.80 4.53 3.36
Income from Discontinued Operations (in dollars per share) 0 0 0 0.30
Net Income (in dollars per share) $ 1.28 $ 1.80 $ 4.53 $ 3.66